A potent human neutralizing antibody Fc-dependently reduces established HBV infections

• DOI: 10.7554/elife.26738
• Publication Date: 2017-09-14T17:00:13Z
• Authors: Dan Li; Wenhui He; Ximing Liu; Sanduo Zheng; Yonghe Qi; Huiyu Li; Fengfeng Mao; Juan Liu; Yinyan Sun; Lijing Pan; Kaixin Du; Keqiong Ye; Wenhui Li; Jianhua Sui
• Keywords: 0301 basic medicine; Hepatitis B virus; QH301-705.5; Science; NTCP; Antibodies, Viral; Antiviral Agents; Chemoprevention; Mice; 03 medical and health sciences; Immunology and Inflammation; antibody; HBV; Animals; Humans; Biology (General); Q; R; Antibodies, Monoclonal; Hepatitis B; Antibodies, Neutralizing; 3. Good health; Disease Models, Animal; Treatment Outcome; Fc receptor; preS1; Medicine; Immunotherapy; Hepatitis Delta Virus; effector function

Hepatitis B virus (HBV) infection is a major global health problem. Currently-available therapies are ineffective in curing chronic HBV infection. and its satellite hepatitis D (HDV) infect hepatocytes via binding of the preS1 domain large envelope protein to sodium taurocholate cotransporting polypeptide (NTCP). Here, we developed novel human monoclonal antibodies that block engagement with NTCP neutralize HDV high potency. One antibody, 2H5-A14, functions at picomolar level exhibited neutralization-activity-mediated prophylactic effects. It also acts therapeutically by eliciting antibody-Fc-dependent immunological effector impose durable suppression viral HBV-infected mice, resulting reductions levels small antigen DNA, no emergence escape mutants. Our results illustrate approach for treatment suggest 2H5-A14 as clinical candidate prevention